Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Miller

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Thymus Composition Predicts Pneumonitis Risk in Lung Cancer TherapyTafadzwa L Chaunzwa, Gokul Krishnan, Kwadwo Amoako-Boadu, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 13, 2026
Real-World Anatomical Outcomes of Suprachoroidal Triamcinolone Acetonide Injections in a Large Retinal Practice over a 4-Year PeriodChase W Miller, Casey A Scroggins, Shannon L Wuller, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Thymus Composition Predicts Pneumonitis Risk in Lung Cancer TherapyTafadzwa L Chaunzwa, Gokul Krishnan, Kwadwo Amoako-Boadu, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 13, 2026
Real-World Anatomical Outcomes of Suprachoroidal Triamcinolone Acetonide Injections in a Large Retinal Practice over a 4-Year PeriodChase W Miller, Casey A Scroggins, Shannon L Wuller, et al.
International Journal of Retina and Vitreous|February 2, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degenerationJoseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Pageof 4